Is MREO or IMUX more profitable?

Mereo BioPharma Group's return on equity of -81.28% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -81.28% -70.45% Immunic N/A -220.75% -132.04%

Is MREO or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -81.28% -70.45% Nkarta N/A -30.90% -24.20%

Is TTRX or MREO more profitable?

Turn Therapeutics' return on equity of 0.00% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A N/A N/A Mereo BioPharma Group N/A -81.28% -70.45%

Do analysts rate ACB or MREO?

Mereo BioPharma Group has a consensus price target of $3.25, indicating a potential upside of 908.38%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mereo BioPharma Group 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25

Mereo BioPharma Group (MREO) Competitors

$0.32 0.00 (-0.83%)

Closing price 04:00 PM Eastern

Extended Trading

$0.33 +0.01 (+1.77%)

As of 07:25 PM Eastern

Compare

MREO vs. IMUX, CGEN, NKTX, TTRX, and ACB

Should you buy Mereo BioPharma Group stock or one of its competitors? MarketBeat compares Mereo BioPharma Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mereo BioPharma Group include Immunic (IMUX), Compugen (CGEN), Nkarta (NKTX), Turn Therapeutics (TTRX), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry.

How does Mereo BioPharma Group compare to Immunic?

Mereo BioPharma Group (NASDAQ:MREO) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Mereo BioPharma Group has higher revenue and earnings than Immunic. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	102.89	-$41.88M	-$0.05	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Mereo BioPharma Group currently has a consensus price target of $3.25, suggesting a potential upside of 908.38%. Immunic has a consensus price target of $47.57, suggesting a potential upside of 215.67%. Given Mereo BioPharma Group's higher possible upside, equities analysts clearly believe Mereo BioPharma Group is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Mereo BioPharma Group has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

In the previous week, Mereo BioPharma Group's average media sentiment score of 0.00 equaled Immunic'saverage media sentiment score.

Company	Overall Sentiment
Mereo BioPharma Group	Neutral
Immunic	Neutral

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by insiders. Comparatively, 5.5% of Immunic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Mereo BioPharma Group's return on equity of -81.28% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
Immunic	N/A	-220.75%	-132.04%

Summary

Mereo BioPharma Group beats Immunic on 8 of the 13 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Compugen?

Mereo BioPharma Group (NASDAQ:MREO) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Mereo BioPharma Group presently has a consensus price target of $3.25, indicating a potential upside of 908.38%. Compugen has a consensus price target of $5.00, indicating a potential upside of 147.52%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Mereo BioPharma Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Compugen has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market.

Compugen has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	102.89	-$41.88M	-$0.05	N/A
Compugen	$72.76M	2.62	$35.34M	$0.37	5.46

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Compugen had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 2 mentions for Compugen and 0 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.00 beat Compugen's score of -0.05 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group	Neutral
Compugen	Neutral

Compugen has a net margin of 47.97% compared to Mereo BioPharma Group's net margin of 0.00%. Compugen's return on equity of 47.72% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
Compugen	47.97%	47.72%	27.51%

Summary

Compugen beats Mereo BioPharma Group on 12 of the 16 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Nkarta?

Mereo BioPharma Group (NASDAQ:MREO) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Mereo BioPharma Group currently has a consensus target price of $3.25, indicating a potential upside of 908.38%. Nkarta has a consensus target price of $10.75, indicating a potential upside of 254.79%. Given Mereo BioPharma Group's higher possible upside, equities analysts clearly believe Mereo BioPharma Group is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Mereo BioPharma Group has higher revenue and earnings than Nkarta. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	102.89	-$41.88M	-$0.05	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

In the previous week, Nkarta had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 3 mentions for Nkarta and 0 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.00 beat Nkarta's score of -0.50 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group	Neutral
Nkarta	Negative

Mereo BioPharma Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 9.8% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nkarta's return on equity of -30.90% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
Nkarta	N/A	-30.90%	-24.20%

Summary

Nkarta beats Mereo BioPharma Group on 10 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Turn Therapeutics has higher earnings, but lower revenue than Mereo BioPharma Group. Turn Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Mereo BioPharma Group	$500K	102.89	-$41.88M	-$0.05	N/A

In the previous week, Turn Therapeutics had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.00 beat Turn Therapeutics' score of -0.36 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Turn Therapeutics	Neutral
Mereo BioPharma Group	Neutral

Turn Therapeutics' return on equity of 0.00% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Mereo BioPharma Group	N/A	-81.28%	-70.45%

62.8% of Mereo BioPharma Group shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Turn Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 33.56%. Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 908.38%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Mereo BioPharma Group beats Turn Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Mereo BioPharma Group has a net margin of 0.00% compared to Aurora Cannabis' net margin of -33.57%. Aurora Cannabis' return on equity of 0.10% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-33.57%	0.10%	0.07%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mereo BioPharma Group has lower revenue, but higher earnings than Aurora Cannabis. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$320.59M	0.55	-$88.13M	-$1.56	N/A
Mereo BioPharma Group	$500K	102.89	-$41.88M	-$0.05	N/A

Aurora Cannabis has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

In the previous week, Aurora Cannabis' average media sentiment score of 0.00 equaled Mereo BioPharma Group'saverage media sentiment score.

Company	Overall Sentiment
Aurora Cannabis	Neutral
Mereo BioPharma Group	Neutral

Mereo BioPharma Group has a consensus price target of $3.25, indicating a potential upside of 908.38%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Mereo BioPharma Group beats Aurora Cannabis on 9 of the 14 factors compared between the two stocks.

Get Mereo BioPharma Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MREO vs. The Competition

Export

Metric	Mereo BioPharma Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$51.44M	$3.45B	$6.47B	$12.12B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-6.45	20.09	24.71	24.00
Price / Sales	102.89	188.42	491.85	90.96
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	1.24	8.28	10.82	6.53
Net Income	-$41.88M	$23.85M	$3.56B	$336.99M
7 Day Performance	10.38%	5.21%	1.67%	-0.22%
1 Month Performance	15.81%	2.19%	0.43%	0.77%
1 Year Performance	-88.24%	60.99%	32.84%	31.57%

Mereo BioPharma Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MREO Mereo BioPharma Group	1.9745 of 5 stars	$0.32 -0.8%	$3.25 +908.4%	-88.6%	$51.44M	$500K	N/A	40
IMUX Immunic	2.508 of 5 stars	$13.69 -2.3%	$47.57 +247.4%	+104.9%	$187.07M	N/A	N/A	70
CGEN Compugen	3.8641 of 5 stars	$1.98 -2.2%	$5.00 +153.2%	+26.2%	$186.74M	$72.76M	5.34	70
NKTX Nkarta	3.2902 of 5 stars	$2.59 -5.7%	$10.75 +315.9%	+57.6%	$185.07M	N/A	N/A	140	Analyst Forecast Gap Down
TTRX Turn Therapeutics	2.2188 of 5 stars	$6.07 -5.5%	$8.00 +31.8%	N/A	$180.83M	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MREO) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mereo BioPharma Group (MREO) Competitors

MREO vs. IMUX, CGEN, NKTX, TTRX, and ACB

How does Mereo BioPharma Group compare to Immunic?

Summary

How does Mereo BioPharma Group compare to Compugen?

Summary

How does Mereo BioPharma Group compare to Nkarta?

Summary

How does Mereo BioPharma Group compare to Turn Therapeutics?

Summary

How does Mereo BioPharma Group compare to Aurora Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mereo BioPharma Group (MREO) Competitors

MREO vs. IMUX, CGEN, NKTX, TTRX, and ACB

How does Mereo BioPharma Group compare to Immunic?

Which has preferable valuation & earnings, MREO or IMUX?

Do analysts recommend MREO or IMUX?

Which has more risk and volatility, MREO or IMUX?

Does the media refer more to MREO or IMUX?

Do insiders & institutionals have more ownership in MREO or IMUX?

Is MREO or IMUX more profitable?

Summary

How does Mereo BioPharma Group compare to Compugen?

Do analysts prefer MREO or CGEN?

Which has more risk and volatility, MREO or CGEN?

Which has stronger earnings & valuation, MREO or CGEN?

Do insiders and institutionals have more ownership in MREO or CGEN?

Does the media refer more to MREO or CGEN?

Is MREO or CGEN more profitable?

Summary

How does Mereo BioPharma Group compare to Nkarta?

Do analysts prefer MREO or NKTX?

Which has better valuation & earnings, MREO or NKTX?

Does the media refer more to MREO or NKTX?

Which has more volatility and risk, MREO or NKTX?

Do institutionals & insiders have more ownership in MREO or NKTX?

Is MREO or NKTX more profitable?

Summary

How does Mereo BioPharma Group compare to Turn Therapeutics?

Which has stronger earnings and valuation, TTRX or MREO?

Does the media favor TTRX or MREO?

Is TTRX or MREO more profitable?

Do institutionals & insiders believe in TTRX or MREO?

Do analysts rate TTRX or MREO?

Summary

How does Mereo BioPharma Group compare to Aurora Cannabis?

Is ACB or MREO more profitable?

Do institutionals and insiders believe in ACB or MREO?

Which has better valuation and earnings, ACB or MREO?

Which has more risk & volatility, ACB or MREO?

Does the media prefer ACB or MREO?

Do analysts rate ACB or MREO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools